180,163 uniQure N.V. $QURE Shares Purchased by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its uniQure stake by 35.1%, buying 180,163 shares to reach 693,693 shares worth approximately $16.76 million. Institutional investors collectively own 78.83% of QURE.
• uniQure reported a quarterly loss of $1.22 per share, missing estimates by $0.40, although revenue of $5.84 million exceeded analyst expectations. Analysts project a full-year loss of $3.82 per share.
• Analyst sentiment is mixed but leans positive: the stock has a consensus “Moderate Buy” rating and an average price target of $53.25, compared with a recent share price of $21.78.

Assenagon Asset Management S.A. lifted its position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 35.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 693,693 shares of the biotechnology company's stock after purchasing an additional 180,163 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.00% of uniQure worth $16,760,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Orbimed Advisors LLC lifted its position in uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company's stock worth $34,926,000 after purchasing an additional 1,398,749 shares during the period. Two Seas Capital LP acquired a new stake in uniQure during the third quarter worth $31,988,000. Siren L.L.C. acquired a new stake in uniQure during the first quarter worth $16,350,000. SG Americas Securities LLC boosted its stake in uniQure by 1,107.3% during the first quarter. SG Americas Securities LLC now owns 776,604 shares of the biotechnology company's stock worth $12,697,000 after buying an additional 712,278 shares in the last quarter. Finally, Kalehua Capital Management LLC bought a new stake in uniQure in the 1st quarter valued at $4,760,000. Institutional investors and hedge funds own 78.83% of the company's stock.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $21.78 on Monday. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The business has a fifty day moving average of $39.26 and a 200-day moving average of $33.93. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The firm has a market cap of $1.51 billion, a PE ratio of -5.43 and a beta of 1.06.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The company had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. During the same quarter in the previous year, the business posted ($0.69) EPS. On average, equities research analysts predict that uniQure N.V. will post -3.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Wolfe Research upgraded shares of uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price target for the company in a research note on Wednesday, July 29th. Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a report on Saturday, September 5th. Barclays lowered uniQure from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $60.00 to $28.00 in a research note on Monday, October 5th. William Blair upgraded uniQure to a "strong-buy" rating in a research note on Wednesday, September 23rd. Finally, UBS Group reissued a "buy" rating and issued a $48.00 target price (up from $27.00) on shares of uniQure in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, uniQure currently has a consensus rating of "Moderate Buy" and an average target price of $53.25.

uniQure Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients' cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure's lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.